Journal
CLINICAL SCIENCE
Volume 135, Issue 3, Pages 465-481Publisher
PORTLAND PRESS LTD
DOI: 10.1042/CS20201511
Keywords
-
Categories
Funding
- Axencia Galega de Innovacion [IN845D 2020/20]
- Spanish Ministry of Economy and Competitiveness [RTI2018-098830-B-I00, RTI2018-094204-B-I00]
- Spanish Ministry of Health [PI17/00828, RD16/0011/0016]
- Spanish Ministry of Health [CIBERNED]
- Galician Government [XUGA, ED431C 2018/10, ED431G/05]
- FEDER (Regional European Development Fund)
Ask authors/readers for more resources
The key link between renin-angiotensin system (RAS) and COVID-19 lies in ACE2, which can increase tissue anti-inflammatory response and serve as the entry receptor for the virus. Controversy surrounds drugs that regulate RAS activity and ACE2, with some drugs potentially increasing levels of ACE2 and promoting the anti-inflammatory RAS axis in the lung. Additionally, drug-induced up-regulation of transmembrane ACE2 expression may be counteracted by inhibiting ADAM17 activity to prevent increased viral entry.
The key link between renin-angiotensin system (RAS) and COVID-19 is ACE2 (angiotensin-converting enzyme 2), which acts as a double-edged sword, because ACE2 increases the tissue anti-inflammatory response but it is also the entry receptor for the virus. There is an important controversy on several drugs that regulate RAS activity and possibly ACE2, and are widely used, particularly by patients most vulnerable to severe COVID-19. In the lung of healthy rats, we observed that candesartan (an angiotensin type-1, AT1, receptor blocker; ARB) and captopril (an ACE inhibitor; ACEI) up-regulated expression of tissue ACE2 and RAS anti-inflammatory axis receptors (AT2 and Mas receptors). This effect was particularly pronounced in rats with metabolic syndrome (obesity, increased blood pressure and hyperglycemia) and aged rats. Treatment of cultures of human type-II pneumocytes with candesartan or captopril induced up-regulation of ACE2 expression in cells. Treatment with viral spike protein induced a decrease in full-length (i.e. transmembrane) ACE2, an increase in levels of a short intracellular ACE2 polypeptide and an increase in ADAM17 activity in cells, together with an increase in levels of soluble ACE2 and major proinflammatory cytokines in the culture medium. Spike protein-induced changes and levels of spike protein internalization in cells were inhibited by pretreatment with the above-mentioned drugs. The results suggest that these drugs increase ACE2 levels and promote the anti-inflammatory RAS axis in the lung. Furthermore, possible up-regulation of viral entry by the drug-induced increase in expression of transmembrane ACE2 is counteracted by additional mechanisms, particularly by drug-induced inhibition of ADAM17 activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available